Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Moderna Inc (NQ: MRNA )

43.66 +2.55 (+6.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today
Via Benzinga
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Top 3 Health Care Stocks That May Explode This Month
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for a Decade
These innovative companies have the tools to rebound. 
Via The Motley Fool
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Pfizer Advances On Its Cancer Journey
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... 
Via Benzinga
Down 13% in 1 Day, Is Moderna Stock in Trouble?
There's no hope of it recovering to its prior heights anytime soon. 
Via The Motley Fool
3 Beaten-Down Stocks Ready for a Comeback
if you're looking for a way to escape the market volatility, here are three stocks that are trading near their 52-week lows with solid catalysts for growth 
Via MarketBeat
Topics Economy
Exposures Economy
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
This strategic play will take time to pay off, but it could keep growth going. 
Via The Motley Fool
Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline
From Robbins LLP
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity Residential. Moderna has been disappointing, but Cramer likes Vertiv and... 
Via Benzinga
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers
S&P 500 hits new record highs amidst expectations for Fed interest rate decision. Small-cap stocks outperform, while uncertainty remains. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Momentum Investing Gives You An Edge, Until It Doesn’t
Since 2020, momentum investing has generated significantly better returns than other strategies. Such is not surprising, given the massive amounts of stimulus injected into the financial system. 
Via Talk Markets
Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?
Wall Street experienced a slightly positive session Tuesday, supported by investor optimism as the Federal Open Market Committee (FOMC) kicked off its two-day meeting, expected to deliver the first... 
Via Benzinga
Topics Economy
Exposures Interest Rates
What's Going On With Moderna Shares Tuesday?
Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 vaccine. 
Via Benzinga
Exposures COVID-19
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and... 
Via Benzinga
Exposures COVID-19
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax. 
Via MarketBeat
Exposures COVID-19 Product Safety
Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
10 worst performing large-cap stocks last week: RTO, ALLY, MRNA, HUM, TSN, BEKE, ADBE, RYAAY, JPM, DVN. Consider impact on your portfolio. 
Via Benzinga
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
This highflier has fallen on hard times recently. 
Via The Motley Fool
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024. 
Via Talk Markets
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
Financial factors aren't the only things that are worth paying attention to. 
Via The Motley Fool
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Moderna held its annual R&D day this week. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight near-term challenges, lowered price targets, and a delayed breakeven to 2028,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.